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Background: The present study evaluated CareStart pLDH Malaria, a three-band rapid diagnostic test detecting
Plasmodium falciparum-specific parasite lactate dehydrogenase (Pf-pLDH) and pan Plasmodium-specific pLDH
(pan-pLDH) in a reference setting.
Methods: CareStart pLDH was retrospectively and prospectively assessed with a panel of stored (n = 498) and fresh
(n = 77) blood samples obtained in international travelers suspected of malaria. Both panels comprised all four
Plasmodium species; the retrospective panel comprised also Plasmodium negative samples. The reference method
was microscopy corrected by PCR. The prospective panel was run side-to-side with OptiMAL (Pf-pLDH/pan-pLDH)
and SDFK60 (histidine-rich protein-2 (HRP-2)/pan-pLDH).
Results: In the retrospective evaluation, overall sensitivity for P. falciparum samples (n = 247) was 94.7%, reaching
98.7% for parasite densities> 1,000/μl. Most false negative results occurred among samples with pure
gametocytaemia (2/12, 16.7%) and at parasite densities≤ 100/μl (7/12, 58.3%). None of the Plasmodium negative
samples (n = 96) showed visible test lines. Sensitivities for Plasmodium vivax (n = 70), Plasmodium ovale (n = 69) and
Plasmodium malariae (n = 16) were 74.3%, 31.9% and 25.0% respectively. Wrong species identification occurred in
10 (2.5%) samples and was mainly due to P. vivax samples reacting with the Pf-pLDH test line. Overall, Pf-pLDH test
lines showed higher line intensities compared to the pan-pLDH lines (67.9% and 23.0% medium and strong line
intensities for P. falciparum). In the prospective panel (77 Plasmodium-positive samples), CareStart pLDH showed
higher sensitivities for P. falciparum compared to OptiMAL (p = 0.008), lower sensitivities for P. falciparum as
compare to SDFK60 (although not reaching statistical significance, p = 0.08) and higher sensitivities for P. ovale
compared to both OptiMAL (p = 0.03) and SDFK60 (p = 0.01). Inter-observer and test reproducibility were good to
excellent.
Conclusion: CareStart pLDH performed excellent for the detection of P. falciparum, well for P. vivax, but poor for
P. ovale and P. malariae.
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In 2009, 225 million cases of malaria occurred with
781,000 deaths, mostly due to Plasmodium falciparum
among children in Africa [1]. In addition, yearly an esti-
mated 30,000 international travellers fall ill with malaria
after returning from malaria-endemic regions [2]. Early
diagnosis and treatment are necessary to prevent severe
malaria and death. Microscopy is the cornerstone for the
diagnosis but requires training and expertise. Malaria
rapid diagnostic tests (RDTs) are an additional value in
the laboratory work-up, both in endemic settings and in
the setting of travel medicine [3,4].
RDTs consist of nitrocellulose strips mostly embedded
in plastic cassettes. When blood and buffer are applied,
the red blood cells are lysed and the targeted antigen
binds to the detecting mouse antibody which is conju-
gated to colloidal gold. This complex moves further
along the nitrocellulose strip until the antigen binds (by
another motif ) to the capture antibody embedded as a
transverse line on the nitrocellulose strip. As a result,
the colloidal gold is concentrated on a small surface and
becomes visible as a purple-red line. The non-bound
conjugated antibodies move further along the strip until
they are captured by goat anti-mouse antibodies, thereby
generating the control line. Two-band RDTs consist of a
control line and a P. falciparum specific test line which
targets either histidine-rich protein-2 (HRP-2) or P. fal-
ciparum specific lactate dehydrogenase (Pf-pLDH).
Three-band RDTs display three lines: a control line, a P.
falciparum-specific line (detection of HRP-2 or Pf-
pLDH) a third line detecting P. vivax (by a P. vivax- spe-
cific pLDH, Pv-pLDH) or an antigen common to all four
species, either aldolase or pan-Plasmodium-specific
pLDH (pan-pLDH).
The present study describes the diagnostic evaluation
of CareStart pLDH Malaria G0121 (AccessBio Inc.,
Monmouth, USA, further referred to as CareStart
pLDH), a three-band RDT targeting Pf-pLDH and pan-
pLDH) in a reference setting.Methods
Study design
CareStart pLDH was evaluated in a non-endemic reference
laboratory on clinical samples obtained in international tra-
velers suspected of malaria. The evaluation consisted of
two parts: a retrospective study on a panel of stored whole
blood samples and a prospective study on fresh whole
blood samples. The prospective samples were run side to
side with two other RDTs used as part of standard labora-
tory work-up of malaria-suspected samples. The reference
method was microscopy corrected by polymerase chain re-
action (PCR) for Plasmodium detection and species identi-
fication. Parasite densities were determined by microscopy.The study design was in compliance with the STARD
guidelines for presentation of diagnostic studies [5].
Patients and materials
The panel was selected from a collection of EDTA anti-
coagulated blood samples which were either obtained in
patients suspected of malaria presenting at the out-
patient clinic of the Institute of Tropical Medicine (ITM,
Antwerp, Belgium) or submitted by other Belgian
laboratories for confirmation in the scope of the national
reference laboratory for Plasmodium. The samples were
obtained in international travellers and natives of en-
demic regions returning from visiting friends and
relatives.
The retrospective panel had been obtained between
February 1996 and May 2011. Samples collected at ITM
were kept at room temperature (< 25°C) for a maximum
of 8 hours before analysis and subsequent storage at
−70°C. Samples submitted from other Belgium labora-
tories had been exposed to ambient temperatures for the
period of shipment which was generally less than 24
hours with a maximum of 48 hours. The selected panel
comprised the four Plasmodium species at different
parasite densities, as well as Plasmodium negative sam-
ples. The latter were obtained in patients suspected of
malaria, but negative for Plasmodium by microscopy,
PCR and RTDs used in the standard diagnostic work-up.
Samples with pure gametocytaemia were included
among the P. falciparum species. Mixed infections were
not considered. The prospective panel included fresh
first samples of all patients diagnosed with malaria by
microscopy between January 2011 and July 2011. Again,
mixed infections were not considered.Reference method
Malaria diagnostics at ITM are accredited to the require-
ments of NBN EN ISO 15189:2007. An expert micro-
scopist assessed all samples for the presence of
Plasmodium parasites, species identification and parasite
density according the World Health Organization
(WHO) standards for microscopy with exception of the
Giemsa staining that was done with pH 8.0 instead of
pH 7.2 [6,7]. Thick and thin blood films were prepared
and examined by light microscopy. A minimum of 200
fields was examined before a blood film was reported
negative. The parasite density was obtained by counting
the asexual parasites against 200 white blood cells
(WBC) in thick blood films and using the WBC count
or, when not available, the standard 8,000 WBC/μl, for
the conversion to parasites/μl [6,7]. Four-primer real-
time PCR was performed on all samples [8]. The result
of microscopy corrected by PCR was considered as the
reference.
Table 2 Interpretation of test results for the non-
falciparum species









Only pan-pLDH True positive /
species mismatch*
No test line visible False negative
or / True Negative
only Pf-pLDH or both
Pf-pLDH and pan-pLDH
species mismatch**
* P. falciparum diagnosed as non-falciparum species.
** Non-falciparum species diagnosed as P. falciparum or as a mixed infection
with P. falciparum.
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In the prospective study, CareStart pLDH was run side-
to-side with two other RDTs used in routine diagnosis.
OptiMAL pLDH (Pan, Pf ) (Biorad, Marnes-la-Coquette,
France), further referred to as OptiMAL, is a three-band
RDT targeting Pf-pLDH and pan-pLDH. SD Bioline Ag
Pf/Pan 05FK60 (Standard Diagnostics, Hagal-Dong,
Korea), further referred to as SDFK60, is a three-band
RDT targeting HRP-2 and pan-pLDH. All RDTs had
been stored between 18°C and 24°C. In case of an absent
control line the test was considered invalid and the sam-
ple was retested. When the test lines were impossible to
read due to poor background clearing, the test was
scored ‘unreadable’ and repeat testing was performed.
For CareStart pLDH, the interpretation of the appear-
ance of one or both test lines in the presence of a con-
trol line is as follows (Table 1–2): the presence of a
unique Pf-pLDH line indicates an infection with P. fal-
ciparum, whereas a unique pan-pLDH test line points to
an infection with one or more of the non-falciparum
species. The presence of both a P. falciparum specific
and pan-Plasmodium test line indicates an infection with
P. falciparum or a mixed infection with P. falciparum
and one or more of the non-falciparum species. A spe-
cies mismatch occurred when a wrong species was
identification.
For the evaluation of CareStart pLDH, kits from two
different lots were used. In the retrospective evaluation
lot numbers AI0IL (n = 350) and DIIML (n = 148) were
used, which expired in December 2011 and March 2012
respectively. In the prospective evaluation lot AI0IL
(n = 98) was used.
Test procedures
Tests were carried out in time controlled batches. They
were performed in compliance with the instructions ofTable 1 Interpretation of test results for P. falciparum
Species identification by microscopy
corrected by PCR
Non-falciparum
P. falciparum (P.vivax, P.ovale,
P.malariae)
or no parasites detected
Only Pf-pLDH False positive




No test line visible False negative
or / True Negative
only pan-pLDH species mismatch*
* P. falciparum diagnosed as non-falciparum species.
** Non-falciparum species diagnosed as P. falciparum or as a mixed infection
with P. falciparum.the manufacturers, except that the transfer devices
included in the kits were replaced by a transfer pipette
(Finnpipette, Helsinki, Finland). Readings were carried
out at daylight assisted by a standard light source. In the
retrospective evaluation readings were subsequently car-
ried out by three trained observers, of whom the first
two performed the RDTs. The first two observers scored
the test at 20 minutes, which is the recommended read-
ing time, followed by the third observer. Photographs of
the batches were taken immediately thereafter and
within 25 minutes after application of the sample. The
observers were blinded to the microscopy, PCR and each
other’s results. In the prospective evaluation the labora-
tory technician who performed microscopy also per-
formed the RDTs and was the single observer.
A scoring system was used to categorize line inten-
sities: negative (N, no visible test line), faint (F, barely
visible), weak (W, paler than the control line), medium
(M, equal to the control line) and strong (S, stronger
than the control line) [9]. Test results were based on
consensus, i.e. an identical score by at least two out of
three readers. In case of no consensus the photographs
were reviewed to conclude.Data management and statistical analysis
Data was recorded on register forms and entered in a
Microsoft Excel database (Microsoft Corporation, Red-
mond, Washington, USA). End points were sensitivity,
specificity, inter-observer agreement and reproducibility.
The interpretation of test results for P. falciparum and
the non-falciparum species is shown in Tables 1 and 2.
Sensitivity and specificity were calculated with 95% con-
fidence interval (C.I.). Proportions were assessed for
statistical significance using the two-tailed Fisher’s exact
test and the McNemar test, for unpaired and paired panels
respectively. A p-value< 0.05 was considered significant.
Table 3 Test results of CareStart pLDH for the
retrospective evaluation (n= 498)
Pf-pLDH line positive
number of samples (%)
Pf-pLDH line negative











160 (64.8) 74 (30.0) 1 (0.4)* 12 (4.9)
P. vivax
(n = 70)
9 (12.9)* 52 (74.3) 9 (12.9)
P. ovale
(n = 69)
22 (31.9) 47 (68.1)
P. malariae
(n = 16)
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densities, lot variation, duration of storage of the samples
and the sensitivity specific per species, multivariate analysis
was done with Stata 11.1 (StataCorp LP, Collage Station,
USA). Inter-observer agreement for both results of positive
and negative readings as well as for line intensity scorings
was expressed by the percentage of overall agreement and
by kappa values for each pair of observers. A kappa be-
tween 0.6 and 0.8 was considered a good agreement, higher
than 0.8 was considered as excellent [9]. Test reproducibil-
ity was evaluated by testing 15 samples representing all
species at varying parasite densities on six occasions.
Additional analysis
All samples that generated invalid and unreadable
results, all samples identified as species mismatch and
all false-negative P. falciparum samples were tested
again with CareStart pLDH in the same conditions as
the initial testing.
Package, labelling and instructions for use
Checklists for assessing quality of packaging, labelling
and information insert were applied [10]. The Flesh Kin-
caid Grade Level was used to score the readability of the
manufacturer’s instructions: it expresses the number of
years of education that is needed to understand the text,
based on measurement of length of words and sentences
[10]. In addition, letter type (open versus closed), font
size, and inter-line spacing were assessed as previously
described [10].
Ethical review
The study was approved by the Institutional Review





The retrospective evaluation consisted of 498 samples
obtained in 498 patients with a median age of 37.0 years
(range 5 months - 78 years), and a male to female ratio
of 1.8:1. Seven children (1.4%) under the age of five were
included. In 427 (85.7%) patients the travel history was
known, 85.5% (365/427) of them had recently returned
from sub-Saharan Africa and 9.8% (42/427) from Asia.
Among the P. falciparum samples, there were 13 with
pure gametocytaemia. The median parasite density of
the remaining 234 P. falciparum samples was 869/μl
(range 10–867,788/μl). The median (range) parasite
densities for the 70 P. vivax samples, the 69 P. ovale and
the 16 P. malariae were 701/μl (15–32,000/μl), 974/μl
(10–10,000/μl) and 473/μl (0.1 - 6,096/μl) respectively.Test characteristics
No invalid test results were obtained. Two RDTs were
scored as unreadable at first analysis, and the results
obtained at repeat testing (which showed regular back-
ground clearing) were used. Table 3 shows the results of
the test lines for all species. Of all P. falciparum samples
nearly two-thirds (160/247, 64.8%) showed both Pf-
pLDH and pan-pLDH test lines. Overall sensitivity for
the detection of P. falciparum was 94.7% (Table 4). Sen-
sitivity increased from 74.1% at parasite densities ≤ 100/
μl to 98.1% and 98.7% at parasite densities> 100/μl and
> 1,000/μl respectively (p< 0.001). The majority of false
negative samples was observed among samples with pure
gametocytaemia (2/12, 16.7%) and at parasite densities≤
100/μl (7/12, 58.3%). The remaining three false negative
P. falciparum samples had parasite densities of 131/μl,
267/μl and 6,161/μl. When samples with pure gametocy-
taemia were excluded, overall sensitivity increased to
95.3%.
For P. vivax, P. ovale and P. malariae, sensitivities were
74.3%, 31.9% and 25.0% respectively (Table 5). Sensitivities
was higher at parasite densities above 500/μl compared to
parasite densities below 500/μl. This difference reached
statistical significance in the case of P. ovale (p = 0.001).
Sensitivities at parasite densities above 500/μl remained
below 50% for both P. ovale and P. malariae.
None of the 96 Plasmodium negative samples showed
a test line (Tables 3 and 5). Wrong species identification
(species mismatch) occurred in 10/402 (2.5%) samples:
one P. falciparum sample (parasite density 2,043/μl)
showed only the pan-pLDH test line and was conse-
quently diagnosed as Plasmodium non-falciparum. Eight
P. vivax samples (parasite densities> 1,000/μl) showed
faint or weak Pf-pLDH lines in addition to the pan-
pLDH test line, they were consequently diagnosed as
P. falciparum, mixed infection not excluded. An
Table 4 Accuracy of CareStart pLDH for the detection of P. falciparum, retrospective evaluation






All P. falciparum samples 247 234 94.7 (91.2-97.2)
Pure Gametocytemia 13 11 84.6 (54.6-98.1)
Asexual parasite density 1-100/μl 27 20 74.1 (53.7-88.9)
Asexual parasite density 101-200/μl 15 14 93.3 (68.1-99.8)
Asexual parasite density 201–1,000/μl 34 33 97.1 (84.7-99.9)
Asexual parasite density >1,000/μl 158 156 98.7 (95.5-99.9)
Asexual parasite density >100/μl 207 203 98.1 (95.1-99.5)
All other species and negative samples 251 9* 96.4 (93.3-98.4)
* All P. vivax samples.
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line of strong line intensity in addition to the pan-pLDH
line.
Multivariate analysis showed no impact of duration of
storage of the samples on the diagnostic sensitivity.
However, differences in RDT lot numbers were observed
for P. falciparum; sensitivities were 96.5% and 86.7% for
lot AIOIL and DIIML respectively (p = 0.019).Intensity of test lines
Among the P. falciparum samples, two-thirds (159/234,
67.9%) of visible test lines showed medium or strong
Pf-pLDH test line intensities; faint test lines mostly (19/
33, 57.6%) occurred at parasite densities< 100/μl (Add-
itional file 1). Likewise, the presence of a unique Pf-
pLDH line was mostly (62/74, 83.8%) observed in P.
falciparum samples with parasite densities< 1,000/μl.
The pan-pLDH test line displayed weaker intensities,




Parasite density≤ 500/μl 17
Parasite density> 500/μl 53
P.ovale 69
Parasite density≤ 500/μl 33
Parasite density> 500/μl 36
P.malariae 16
Parasite density≤ 500/μl 8
Parasite density> 500/μl 8
P.falciparum and negative samples 343
P. falciparum 247
No parasites detected 96displaying medium or strong line intensities (Additional
file 2).
For the non-falciparum samples that showed a visible
pan-pLDH line (n = 87), the distribution of line inten-
sities was as follows: faint 20.7%, weak 34.5%, medium
18.4% and strong 26.4%. Of note, P. vivax samples
accounted for the vast majority (31/39, 79.4%) of pan-
pLDH test lines with medium or strong line intensities
(Additional file 2).Inter-observer agreement and reproducibility
The overall agreement and kappa values between pairs
of observers were excellent (> 0.80) for both positive
and negative results and line intensity readings and for
both Pf-pLDH and pan-pLDH test lines, except for one
agreement that was scored as good (kappa value = 0.79).
Test results were reproducible (Additional file 3 and
Additional file 4) and all discordances in line intensity
















1 99.7 (98.4 -100)
1 99.6 (97.8 -100)
0 100 (96.2 -100)







All P. falciparum samples 49 46 91.8 (80.4-97.7)












36 36 100 (90.3-100)
Asexual parasite
density >100/μl
42 40 95.2 (83.8-99.4)
All non-falciparum species 28 22* 78.6 (59.1-91.7)
Parasite density≤ 500/μl 3 1
Parasite density> 500/μl 25 21 84.0 (63.9-95.5)
* Miss diagnosed two P.vivax samples that showed both test lines, and missed
four P. ovale samples.
Table 8 Diagnostic sensitivities of the different RDTs for










CareStart pLDH 46 93.9 (83.1-98.7)
OptiMAL 39 79.6 (65.7-98.8)
Heutmekers et al. Malaria Journal 2012, 11:204 Page 6 of 10
http://www.malariajournal.com/content/11/1/204Prospective evaluation
Sample collection
The prospective evaluation consisted of 77 Plasmodium
positive samples. Males represented 62.3% of the patients,
and the median age was 35 years (range 4 months -
68 years). Three children (4%) under the age of five were
included. In 51 patients (66.2%) the travel history was
known, of which 76.5% (39/51) recently returned from
Sub-Saharan Africa and 21.6% (11/51) from Asia. The
sample collection contained all four Plasmodium species;
among the P. falciparum samples (n = 49) there was one
with pure gametocytaemia. The median parasite densities
(range) of P. falciparum, P. vivax (n = 16), P. ovale
(n = 11) and P. malariae (n = 1) samples were 6,687/μl
(27 – 665,432/μl), 2,473/μl (507–20,953/μl), 858/μl (22–
7,292/μl) and 612/μl respectively.
Test characteristics
There were no invalid neither unreadable test results.
Table 6 shows the number of visible test lines for all spe-
cies. Of all P. falciparum samples two-thirds (33/49,
67.3%) displayed both Pf-pLDH and pan-pLDH test lines.
Table 7 displays the sensitivity for the P. falciparum
and the non-falciparum samples. Seven false negative
results occurred, of which three P. falciparum samples
with parasite densities of 32 μ/l, 130 μ/l and 267 μ/l and
four P. ovale samples with parasite densities of 22 μ/l,
278 μ/l, 609 μ/l and 1,516 μ/. Two P. vivax samples (2/
77, 2.6%, with parasite densities of 2,508/μl and 11,578/
μl) showed a weak and a medium Pf-pLDH test line re-
spectively in addition to a pan-pLDH line. Both samples
were obtained from members of a family who had re-
cently returned from India.
In Table 8 the diagnostic sensitivities of the CareStart
pLDH, OptiMAL and SDFK60 are presented. For P. fal-
ciparum, diagnostic sensitivity of CareStart pLDH was
higher as compared to OptiMAL (p = 0.008) and tended
to be lower compared to SDFK60 (p = 0.08). OptiMALTable 6 Test results of CareStart pLDH for the
prospective evaluation (n= 77)
Pf-pLDH line positive
number of samples (%)
Pf-pLDH line negative











33 (67.4) 13 (26.5) 3 (6.1)
P. vivax
(n = 16)
2 (12.5)* 14 (87.5)
P. ovale
(n = 11)




* Species mismatch.and SDFK60 both detected all 16 P. vivax samples,
whereas CareStart pLDH missed two of them (p = 0.2).
Conversely, CareStart pLDH performed significantly bet-
ter for the detection of P. ovale compared to OptiMAL
(p = 0.03) and SDFK60 (p = 0.01).SDFK60 49 100 (92.8-100)
P. vivax
(n = 16)
CareStart pLDH 14 87.5 (61.7-98.5)
OptiMAL 16 100 (79.4-100)
SDFK60 16 100 (79.4-100)
P. ovale
(n = 10)
CareStart pLDH 6 60.0 (26.2-87.8)
OptiMAL 1 10.0 (0–44.5)






* One P. ovale sample was not tested with OptiMAL and SDFK60.
Figure 1 Information insert of CareStart pLDH, instructions for
use, interpretation: the figure displays the interpretation of test
results. The following shortcomings are observed: (i) upper right:
C + 2: correct interpretation is “Plasmodium non-falciparum” instead
of “P. vivax”; (ii) under right: C + 2 + 1: correct interpretation is “P.
falciparum, mixed species infection is not excluded”. Not all line
combinations pointing to an invalid test are depicted and there is a
typographical error in the term “invalid” (under left).
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Eleven out of 12 false negative P. falciparum samples
were available for retesting: two of them (parasite
densities 32/μl and 6,161/μl) showed a faint or weak Pf-
pLDH test line, the other nine samples (all with parasite
densities below 1,000/μl) showed no visible test line, as
upon initial testing.
Retesting of samples with species mismatch revealed
the following: the P. falciparum sample initially identified
as non-falciparum (parasite density 2,043/μl) consistently
showed a unique pan-pLDH test line upon repeat testing.
Among the P. vivax samples that showed both Pf-pLDH
and pan-pLDH test lines upon initial testing (n = 9), two
yielded identical results while seven did not show the Pf-
pLDH line upon retesting. Of note, six of the latter ones
were tested with lot number DIIML whereas initial
testing was performed with lot number AIOIL.
Package, labelling and information insert
With regard to quality of packaging, labelling and infor-
mation inserts, the following observations were made: a
CE representative was not mentioned and the CE mark
was not printed in the correct format. Secondly, the
names of the test kit as displayed on information inserts,
boxes, the device blisters and buffer vials showed
differences (box: “pLDH 3 lines (pan/Pf)”; package insert:
“CareStart pLDH”, device blister: “pLDH (pan/Pf) ”, de-
vice: no name; buffer “buffer assay”). Further, box and
labels were not humidity resistant and the label on the
buffer vials did not list the test kits name, expiry date nor
lot number.
The instructions for use did not mention (i) to check
expiry date and saturation of silica gel, (ii) to write the
patient identification on the cassette and (iii) to use only
the buffer vial provided in the kit. In addition, the illus-
trations of the depicted cassettes showed slight
differences with the real RDT device: (i) the labelling of
wells and reading windows was not depicted and (ii) the
shape of the sample well was depicted as oval instead of
rectangular. The test lines were depicted in a bright red
color, whereas in reality they are purple-red. In addition,
there were shortcomings in the interpretation of test
lines (Figure 1). Readability expressed as Flesh Kincaid
Grade Level was 8.68, a closed letter type was used and
font size was 8 with an interline spacing of 2.
Discussion
The present study assessed the performance of CareStart
pLDH in a reference setting, retrospectively on stored
and prospectively on fresh samples, obtained in inter-
national travelers suspected of malaria. Overall
sensitivity for P. falciparum was> 90%, and reached
> 98% at parasite densities above 100/μl. False-negative
results mainly occurred at parasite densities< 100/μl.One P. falciparum sample was wrongly diagnosed as a
non-falciparum species. Overall sensitivity for P. vivax
was good, but poor for P. ovale and P. malariae.
Evaluating a RDT in a reference setting is a logic step
preceding field studies though it has inherent limitations
[9,11-13]. For instance, the retrospective design made it
impossible to retrieve clinical information such as treat-
ment and interfering factors like rheumatoid factor that
might explain for unexpected results. Next, unlike HRP-
2 - which is a very stable antigen [14] - pLDH may de-
grade during long storage [12], although such an effect
was not demonstrated in the present study. Finally, the
application of strict interpretation criteria influenced test
outcomes: first, P. falciparum samples with pure game-
tocytaemia were included among the positive samples.
This is meaningful in the scope of travel medicine [15],
but tends to decrease the diagnostic sensitivity of the
RDT studied as was the case in the present study.
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negatives, despite the fact that the diagnosis of malaria
was confirmed. Categorizing the samples with species
mismatch as true positives would have increased the
sensitivity for P. vivax in the retrospective evaluation
from 74.3% to 87.1%.
CareStart pLDH was previously evaluated by the
World Health Organization (WHO) and the Foundation
for Innovative New Diagnostics (FIND) [16]: detection
of P. falciparum and P. vivax was assessed with diluted
samples at fixed parasite densities. The detection rates at
low parasite densities (200/μl) were 88.9% and 91.4% for
P. falciparum and P. vivax respectively. At high parasite
densities (2,000/μl or 5,000/μl) the detection rate was
100% for both species. In addition, three field studies
have reported on CareStart pLDH: in Myanmar, Ashley
and coworkers reported sensitivities of 90.5% and 78.9%
for P. falciparum and P. vivax samples respectively [17].
In Madagascar, Ratsimbasoa and coworkers found sensi-
tivities of 97.0% for P. falciparum but included too few
non-falciparum samples for calculation of sensitivity
[18]. The high sensitivity for P. falciparum in their study
as compared to the present can be explained by several
facts: in the study of Ratsimbasoa, (i) samples with pure
gametocytaemia were excluded, (ii) any visible test line
was considered as a correct identification, and (iii) the
mean parasite density (6,564/μl) was higher [18]. A third
study from Sierra Leone that examined children under
five years of age: CareStart pLDH showed a sensitivity of
99.4% for P. falciparum [19]. High parasite densities
(median 264,000/μl) in that study may have accounted
for the high sensitivity.
Unlike these previous studies the present study
included all four Plasmodium species.
CareStart pLDH tended to a lower sensitivity for P.
falciparum when run side-to-side with the HRP-2 based
SDFK60. This is not unexpected, as HRP-2 based RDTs
are ascribed a higher sensitivity at low parasite densities
[20]. For P. falciparum, all but one false-negative results
with CareStart pLDH occurred in samples with parasite
densities below 100/μl. Sensitivities of CareStart pLDH
for the detection of P. vivax were lower in the retro-
spective as compared to the prospective evaluation. Ap-
parently, this was not due to an effect of samples storage
at – 70°C, but could be explained by (i) lower parasite
densities in the retrospective panel and (ii) cross-
reaction of P. vivax samples with the Pf-pLDH line
(tested with lot AIOIL), which were consequently cate-
gorized as false-negatives in the retrospective evaluation.
If these cross-reactions were disregarded, the sensitivity
of CareStart pLDH for the detection of P. vivax was
good. Despite the fact that most cross-reactions with the
Pf-pLDH test line occurred in lot AIOIL, they were also
observed with lot DIIML and both observations – lot-to-lot differences and cross reactions – are of concern.
Sensitivity for the P. ovale and P. malariae species was in
line with results described for other RDTs [12,15,21,22].
Of note, in the prospective evaluation, CareStart pLDH
performed better than OptiMAL and SDFK60 for the
detection of P. ovale. The different options proposed re-
cently by Piper and co-authors for the improvement of
the specificity and the sensitivity of the pLDH based
malaria RDTs (optimization of the buffer conditions and
solid support matrices, or even the use of alternative
antibodies that have different binding characteristics)
should be taken into account by the manufacturer [23].
The differences of sensitivity for the Plasmodium spe-
cies were reflected in the distribution of line intensities:
for P. falciparum samples, approximately two-thirds of
Pf-pLDH lines were well visible (strong to medium line
intensities), as were half of pan-pLDH lines in the case
of P. vivax. By contrast, the majority of P. ovale and P.
malariae samples with visible pan-pLDH lines had faint
or weak line intensities. Faint or weak test lines are a
concern particularly in resource limited settings, as they
are difficult to be discerned in poor light conditions and
tend to be disregarded as negative. The lower sensitivity
of pan-pLDH test line intensities in the case of P. ovale
and P. malariae compared to P. vivax may be caused by
a lower affinity of the pan-pLDH antibodies for the
former species [23].
In addition to the differences in cross-reactions of
P. vivax with the Pf-pLDH line mentioned above, there
was also a difference in diagnostic sensitivity for detec-
tion of P. falciparum between both lots tested. Lot-to-lot
variation in RDTs is a well-known issue in performance,
monitoring and quality control of RDTs [13,16]. As slight
– but important – differences between lots such as those
presently observed will probably go undetected by rou-
tine lot control procedures, efforts should be made at
the level of manufacturing and post-marketing surveil-
lance to assure equal performance of different RDT lots.
Improvements in package and labelling of CareStart
pLDH should be considered, which can be done even at
low-cost. The similarity of RDT boxes of different
CareStart RDTs from AccessBio was confusing, espe-
cially since the individual test names were not printed
on the RDT blisters, cassettes and buffer vials. The
interpretation section of the package insert contained
the same error as previously described for the CareStart
Malaria pLDH/HRP2 kit [4]. As was the case for other
instruction leaflets described previously, the CareStart
pLDH letter type (closed), font size (8) and Flesh Kincaid
score (8.9) were below expectations, particularly when
use in resource poor settings is intended: as a compari-
son, for patient education materials and health related
information sheets, font sizes of ≥ 12 and Flesh Kincaid
Grade Levels ≤ 6 are recommended [10].
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nostic setting? Most RDTs that diagnose P. falciparum
are targeting HRP-2, which is known to be detected at
lower parasite densities compared to Pf-pLDH [20]. One
comparative study described lower heat stability for the
Pf-pLDH based RDTs compared to HRP-2 based tests
[24], but the recent Round 3 of the WHO/FIND evalu-
ation did not confirm this association and CareStart
pLDH scored equal to HRP-2 based RDTs in the heat-
stability assessment [16]. HRP-2 based RDTs have their
limitations: HRP-2 gene deletions described in the Peru-
vian Amazon may impede their use [25], persistence of
HRP-2 up to 43 days after a successful treatment
decreases the diagnostic value of a positive result in en-
demic settings [20] and unlike Pf-pLDH based RDTs
they are susceptible to the prozone effect (false negative
or faint test lines at high parasite densities) [26,27]. In
combination with its good performance for the detection
of P. vivax, CareStart pLDH may be an alternative to
other well-described HRP-2 three band RDTs in the
diagnostic setting in non-endemic areas. Despite being
better than the other two RDTs which were run side-to-
side, it should be reminded that its performance for the
detection of P. ovale and P. malariae is poor.
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